{"id":"https://openalex.org/W4361869923","doi":"https://doi.org/10.1158/0008-5472.22379679","title":"Supplementary Figure Legends 1-3 from Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression","display_name":"Supplementary Figure Legends 1-3 from Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression","publication_year":2023,"publication_date":"2023-03-30","ids":{"openalex":"https://openalex.org/W4361869923","doi":"https://doi.org/10.1158/0008-5472.22379679"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.22379679","doi":"https://doi.org/10.1158/0008-5472.22379679","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22379679","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_Legends_1-3_from_Antitumor_Efficacy_of_the_Novel_RAF_Inhibitor_GDC-0879_Is_Predicted_by_BRAF_sup_V600E_sup_Mutational_Status_and_Sustained_Extracellular_Signal-Regulated_Kinase_Mitogen-Activated_Protein_Kinase_Pathway_S/22379679/1/files/39825078.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_Legends_1-3_from_Antitumor_Efficacy_of_the_Novel_RAF_Inhibitor_GDC-0879_Is_Predicted_by_BRAF_sup_V600E_sup_Mutational_Status_and_Sustained_Extracellular_Signal-Regulated_Kinase_Mitogen-Activated_Protein_Kinase_Pathway_S/22379679/1/files/39825078.pdf","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5010844468","display_name":"Klaus P. Hoeflich","orcid":"https://orcid.org/0009-0008-8801-2765","observed_orcids":["https://orcid.org/0009-0008-8801-2765"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Klaus P. Hoeflich","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006906885","display_name":"Sylvia Herter","orcid":"https://orcid.org/0000-0002-2446-696X","observed_orcids":["https://orcid.org/0000-0002-2446-696X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sylvia Herter","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073170085","display_name":"Janet Tien","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Janet Tien","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Leo Wong","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Leo Wong","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112905032","display_name":"Leanne Berry","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Leanne Berry","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Jocelyn Chan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jocelyn Chan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040867393","display_name":"Carol Lynn O'Brien","orcid":"https://orcid.org/0000-0002-0828-5376","observed_orcids":["https://orcid.org/0000-0002-0828-5376"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carol O'Brien","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074916693","display_name":"Zora D. Modrusan","orcid":"https://orcid.org/0009-0003-5647-5195","observed_orcids":["https://orcid.org/0009-0003-5647-5195"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zora Modrusan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088898639","display_name":"Somasekar Seshagiri","orcid":"https://orcid.org/0000-0003-4272-6443","observed_orcids":["https://orcid.org/0000-0003-4272-6443"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Somasekar Seshagiri","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037266029","display_name":"Mark R. Lackner","orcid":"https://orcid.org/0009-0001-4442-7343","observed_orcids":["https://orcid.org/0009-0001-4442-7343"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Lackner","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028575353","display_name":"Howard Marvin Stern","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Howard Stern","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027966349","display_name":"Edna F. Choo","orcid":"https://orcid.org/0000-0003-4200-8302","observed_orcids":["https://orcid.org/0000-0003-4200-8302"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Edna Choo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076742603","display_name":"Lesley J. Murray","orcid":"https://orcid.org/0000-0001-7563-3695","observed_orcids":["https://orcid.org/0000-0001-7563-3695"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lesley Murray","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103054591","display_name":"Lori S. Friedman","orcid":"https://orcid.org/0000-0001-9127-9892","observed_orcids":["https://orcid.org/0000-0001-9127-9892"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lori S. Friedman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5036398076","display_name":"Marcia P. Belvin","orcid":"https://orcid.org/0000-0002-4447-9629","observed_orcids":["https://orcid.org/0000-0002-4447-9629"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marcia Belvin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/raf-inhibitors","display_name":"RAF inhibitors","score":0.8519999980926514},{"id":"https://openalex.org/keywords/braf-v600e-mutation","display_name":"BRAF V600E mutation","score":0.9869999885559082},{"id":"https://openalex.org/keywords/mapk-erk-pathway","display_name":"MAPK/ERK pathway","score":0.8410000205039978},{"id":"https://openalex.org/keywords/antitumor-efficacy","display_name":"antitumor efficacy","score":0.9070000052452087},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.7360000014305115},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.6439999938011169},{"id":"https://openalex.org/keywords/braf-mutant-melanoma","display_name":"BRAF-mutant melanoma","score":0.5770000219345093}],"concepts":[{"id":"https://openalex.org/C28406088","wikidata":"https://www.wikidata.org/wiki/Q5571762","display_name":"Extracellular","level":2,"score":0.650740385055542},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.49310776591300964},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.34093743562698364},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.32946357131004333},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3269602656364441},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.30455249547958374},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.27399781346321106}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/0008-5472.22379679","doi":"https://doi.org/10.1158/0008-5472.22379679","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22379679","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_Legends_1-3_from_Antitumor_Efficacy_of_the_Novel_RAF_Inhibitor_GDC-0879_Is_Predicted_by_BRAF_sup_V600E_sup_Mutational_Status_and_Sustained_Extracellular_Signal-Regulated_Kinase_Mitogen-Activated_Protein_Kinase_Pathway_S/22379679/1/files/39825078.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/0008-5472.22379679","doi":"https://doi.org/10.1158/0008-5472.22379679","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22379679","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_Legends_1-3_from_Antitumor_Efficacy_of_the_Novel_RAF_Inhibitor_GDC-0879_Is_Predicted_by_BRAF_sup_V600E_sup_Mutational_Status_and_Sustained_Extracellular_Signal-Regulated_Kinase_Mitogen-Activated_Protein_Kinase_Pathway_S/22379679/1/files/39825078.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.6240000128746033,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361869923.pdf","grobid_xml":"https://content.openalex.org/works/W4361869923.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4361822300","https://openalex.org/W1967953130","https://openalex.org/W1913521652","https://openalex.org/W4361234490","https://openalex.org/W4396785740","https://openalex.org/W4361234424","https://openalex.org/W2023363762","https://openalex.org/W4361235264"],"abstract_inverted_index":{"Supplementary":[0],"Figure":[1],"Legends":[2],"1-3":[3],"from":[4],"Antitumor":[5],"Efficacy":[6],"of":[7],"the":[8],"Novel":[9],"RAF":[10],"Inhibitor":[11],"GDC-0879":[12],"Is":[13],"Predicted":[14],"by":[15],"BRAFV600E":[16],"Mutational":[17],"Status":[18],"and":[19],"Sustained":[20],"Extracellular":[21],"Signal-Regulated":[22],"Kinase/Mitogen-Activated":[23],"Protein":[24],"Kinase":[25],"Pathway":[26],"Suppression":[27]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2023-04-05T00:00:00"}